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Introduction
Chemotherapy-related hepatic sinusoidal obstruction syndrome (SOS, previously named veno-occlusive disease or VOD) is one of the limiting factors in the otherwise highly effective use of Oxaliplatin (OX) for patients with colorectal liver metastases (1) (2) (3) . Its pathogenesis, preoperative diagnosis and prevention are thus the subject of intense investigation. In fact, since our initial report (1) , several groups have confirmed the existence of OX-related SOS in 25-36% of treated patients. This has led to concerns that OX-associated hepatotoxicity may decrease the chances of curative liver surgery by increasing morbidity through preoperative hemorrhage, post operative liver failure, delayed regeneration and portal hypertension (4) (5) (6) (7) (8) (9) (10) (11) (12) (13) . Rare fatal cases have been reported, inducing a group of experts to publish a cautionary note on the use of chemotherapy before surgical liver resection (14) . SOS is morphologically characterized by centrilobular sinusoidal congestive dilatation and perisinusoidal hemorrhage, occasionally associated with perisinusoidal fibrosis and /or centrilobular hepatic vein fibrotic obstruction, nodular regenerative hyperplasia (NRH) or peliosis (15) (16) (17) .
A rat model based on gavage with monocrotaline (a pyrrolizidine alkaloid) has made an important contribution to understanding SOS pathogenesis, both at the morphological and biochemical levels. Thus this model had shown that the main injury occurs in the hepatic sinusoids and that centrilobular vein involvement is not essential, leading to the replacement of the term VOD (18) . Toxic injury to sinusoidal endothelial cells (SECs) is the key initiating event, followed by alterations of the perisinusodial space. SECs initially round up and detach, allowing erythrocytes to penetrate the perisinusoidal space with further dissection of the sinusoidal lining. embolize downstream within the sinusoidal lumen towards the centrilobular vein (19) .
Microcirculation plugging causes sinusoidal obstruction, a reduction of blood flow in the sinusoids, increasing portal pressure (20) , leading to liver metabolic dysfunction, and affecting the viability of parenchymal cells through hypoxia (15) (16) (17) . In humans, morphological studies have confirmed that the sinusoids are the main site of injury.
The aim of the present study was to gain further insight into the pathogenesis of SOS in humans using a molecular approach (global gene analysis with Affymetrix microarrays) to identify key genes through alterations in their mRNA levels. The clinical impact and the availability of human surgical liver specimen led us to study SOS lesions in CRLM surgical resection treated preoperatively by OX-based chemotherapy. We compared livers with severe OX related SOS to livers treated with OX without SOS, and to histologically normal livers.
Materials and methods

Patients and liver specimen
From the files of the Department of Pathology of University Hospitals of Geneva, Switzerland and of Cochin Hospital of Paris, France, three groups of patients with CRLM were established, matched for sex and age. Group 1 (n=20) was composed of patients treated with preoperative OX-based chemotherapy with histologically confirmed severe SOS (figure 1), based on our previous studies (1, 2) . Group 2 (n=20) was composed of patients treated by OX-based chemotherapy but without SOS. Group 3 (n=20) was composed of cases treated by surgery alone, and without histological lesions. For group 1 and 2, the protocol used was exclusively OX in 
Microarray analysis
All snap frozen liver specimens from the selected cases were obtained from the biobanks of Cochin and Geneva Hospitals and reviewed by frozen section to confirm the presence (for group 1) or the absence (for group 2 and 3) of SOS in the frozen samples. Total RNA was extracted from 25 μm sections of surgical specimen using TRIzol (Invitrogen, Carlsbad, USA). RNA quality was assessed using an Agilent 2100
Bioanalyser with an RNA 6000 Nano LabChip kit. There was no obvious difference in RNA quality between the specimens from patients treated at the 2 centers. A RNA integrity number (RIN) was calculated for each sample of RNA and only high-quality samples were used for microarray hybridization, corresponding to intact RNA (n=23 samples). We generated a hybridization mixture containing 15 μg of double-stranded biotinylated cDNA and hybridized it to GeneChip HG U133 Plus 2.0 (Affymetrix). The data was RMA normalized (21) As a first quality control of the dataset we performed a 1-way ANOVA (tested factor: group) and we visualized the result by hierarchical clustering in the Partek Genomics Suite (Partek) using the Pearson correlation similarity measure and average linkage algorithm (figure 2). Following this analysis, samples from groups 2 and 3 were merged.
To assess the difference in gene-expression values between cases (group 1) and controls (groups 2 & 3), we performed a Welch t-test in Partek Genomics Suite. P- values were corrected for multiple testing by use of the false-discovery rate (FDR) method of Benjamini and Hochberg (22) . We applied a conservative significance threshold of 5% FDR associated with fold change value ≥ 1.5.
The gene expression data can be found in ArrayExpress (http://www.ebi.ac.uk/microarray-as/ae) Accession No.:E-MTAB-503
Network and gene ontology analyses
Pathway analysis of the genes, which were identified as differentially expressed by microarray experiment was undertaken using the Ingenuity Pathway Analysis software (http://www.ingenuity.com) as previously described (23) . All p-values are calculated using the right-tailed Fisher exact test.
Real-time quantitative PCR analysis
To validate our microarray results and further clarify the difference in the expression of the selected genes, we carried out a real-time RT-PCR on additional samples. cDNA was synthesized from 1 ug of total RNA using random hexamers and Supercript III reverse transcriptase (Invitrogen) following supplier's instructions.
Amplicons were designed using the software Primer Express v 2.0 (Applied Biosystems) with default parameters. Amplicons sequences were aligned against the human genome by BLAST to ensure that they were specific for the gene being 
Results
Microarray analysis
To gain insights into the pathogenesis of SOS, we compared expression profiles of one group of 11 human liver tissues with OX-related SOS with 2 control groups of histologically normal livers, one having received preoperative OX-chemotherapy but with no hepatic toxic lesions (n=7), the other without preoperative chemotherapy (n=5).
A hierarchical clustering of the 3 groups on the basis of similarity in the expression pattern of genes selected by ANOVA yielded two major clusters that separated samples with histologically severe SOS (group1) from histologically normal livers (group 2 and 3) (figure 2a). This result underlines the fact that SOS status has a greater impact on the expression profile than the presence or absence of OXbased chemotherapy. Based on this observation, groups 2 and 3 were pooled together for further analysis.
These analyses produced a list of 913 genes that were differentially expressed between SOS and controls (FDR adjusted p-value ≤ 0.05), 613 statistically upregulated (see Supporting information, Table S1 ) and 300 statistically down-regulated (see Supporting information, Table S2 ) by more than 1. Ingenuity Pathway Analysis tool was used to examine functional associations between genes and revealed that several pathways implicated with high significance in human SOS.
Biological pathway analysis
IPA revealed significant up-regulation of expression in SOS compared to controls in genes involved in acute phase response pathway (p=0.00002) (see Supporting information, Table S3 ), notably affecting the IL-6 pathway (IL-6, IL6ST, LBP, STAT3).
The relative over-expression of STAT3 and IL-6 mRNA was confirmed by quantitative RT-PCR experiments that compared the expression levels of samples from group 1 (OX-related SOS n=20) with those observed group 2 (treated by OX-based chemotherapy but without SOS, n=20) and group 3 (treated by surgery alone, and without histological lesions, n=20) (p<0.001) (figure 3).
IPA revealed other biological pathways implicated in SOS with the coagulation system reaching high significance (p=0.0001), notably with up-regulation of genes such as SERPINE1, THBD, F3, PLAU and VWF (see Supporting information, Table   S4 ) and the oxidative stress pathways (p=0.006) with up-regulation of genes such as JUN, SOD2. RT-PCR confirmed over expression of SERPINE1, VWF and SOD2 (figure 4) and was concordant with the microarray data.
IPA analysis also showed activation of the hepatic fibrosis/hepatic stellate cell activation pathway (p=0.0002) (see Supporting information, Table S5 Several genes involved in angiogenesis and hypoxia were also significantly over expressed. HIF1A and VEGF-C were upregulated in SOS (see Supporting information, Table S1 ), while VEGF-A and B, ANGPT1 and 2, NOS3 showed no significant changes. RT-PCR was concordant with the microarray data, notably for the increased HIF1a mRNA in SOS and the significant increase in VEGF-C RNA in both groups 1 and 2 compared to group 3 (figure 7). VEGF-A mRNA was present in the 3 groups, with no significant increase in SOS (figure 7).
Several cytochrome p450 enzyme mRNAs were down-regulated (see Supporting information, Table S7 ). RT-PCR for CYP7A1 showed excellent concordance with the microarray data (data not shown). 
Discussion
To our knowledge, this is the first study to investigate the molecular mechanism of OX-related hepatotoxicity in humans using Affymetrix microarrays to evaluate quantitative gene expression profiles. The investigation provides new insights into the biological and cellular mechanisms involved in chemotherapy related SOS in humans.
We identified 913 genes differentially expressed in OX-related-SOS compared to 2 control groups with histologically normal livers. Interestingly, the two latter groups, one composed of patients who had received preoperative OX for CRLM but who did not develop toxic liver injury and the other composed of patients who had been treated by surgery alone, without chemotherapy, did not segregate on hierarchical clustering. Thus SOS can readily be distinguished from normal liver not only according to its morphological characteristics but also to its molecular configuration.
To pinpoint important functional networks and ontologies, genes over and under expressed in SOS were analyzed using the Ingenuity Pathway Analysis tool. The canonical pathways that were primarily implicated were acute phase response signaling, coagulation system, hepatic fibrosis/hepatic stellate cell activation and oxidative stress. We validated on additional samples 14 of the main deregulated genes 
hepatotoxicity (24) . Interestingly, the IL-6 pathway may also be activated in response to toxic damage, where it plays a critical role in hepatic regeneration and hepatoprotection, or to ischemic injury. Both of these effects appear to be mediated through the actions of STAT 3 that blocks apoptosis, reduces oxidative injury (25) and maintains capillary integrity (26) . An equivalent role could occur in SOS where the oxidative stress pathway is activated and ischemia is present. Interestingly the STAT 1 and STAT 2 genes were also both upregulated in SOS. STAT1 contributes to liver inflammation and injury and to suppression of liver regeneration (25) . Further studies on animal models are needed to understand better STAT function in SOS pathogenesis, both at level of apotosis and of liver regeneration impairment.
Interestingly, the highest mRNA up-regulation in SOS was observed for the chemokine CCL20. Interactions of CCL20 and its receptor CCR6, expressed in colorectal cancer, may play a role in development of metastasis by promoting cancer cell proliferation and migration (27, 28) and increased expression of CCL20 has been reported in livers of patients with CRLM (29) . These studies, however, did not address the effect of preoperative chemotherapy on this system. In our study, hepatic CCL20 expression could not be explained exclusively by the presence of CRLM, its level being higher in patients with SOS than in patients with CRLM alone. Immunohistochemistry demonstrated CCL20 expression in macrophages but not in endothelial cells (30) . In monocytes/macrophages, CCL20 is a hypoxia-inducible gene as illustrated by ischemic/hypoxic transcriptome studies (31,32) where it constitutes an important mechanism to promote recruitment of specific leukocyte subsets at pathological sites. 
